江苏康宁杰瑞生物制药有限公司 Mediaroom

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016

SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announc...

2026-03-20 10:04 2015

Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer

SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announc...

2026-03-18 21:43 2894

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2026-03-17 10:32 3357

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE

SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2026-03-13 09:53 3537

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer

SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the...

2026-03-11 09:38 2952

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2026-02-14 20:58 10351

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology

SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that...

2026-01-27 09:58 5790

Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE

SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that...

2025-12-29 13:52 4743

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC

SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2025-12-20 12:54 6192

Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE

SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2025-12-18 10:26 3173

Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held

SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 99...

2025-12-10 14:20 2347

Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego

SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2...

2025-11-06 12:05 1878

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC

SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...

2025-10-28 09:46 1431

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer

SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2025-10-27 09:51 1420

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2025-10-24 12:56 1451

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966....

2025-10-20 13:21 1377

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2025-10-20 13:15 1602

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that...

2025-10-18 14:59 2452

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced tha...

2025-09-12 09:51 1775

Alphamab Oncology Reports 2025 Interim Results and Business Highlights

SUZHOU, China, Aug. 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported inter...

2025-08-29 09:53 2731

Latest News